The Current Big Thing is Really Small – A Review on Nanomaterials in Medicine with an Overview of Metal Oxide Nanomaterial Toxicity
Nanotechnology is being employed in the pharmaceutical field for many reasons, but perhaps the leading goals are to improve drug solubility/bio-availability and/or delivery to various sites of action and development of advanced diagnostic and therapeutic devices. Among various nanomaterials, metal oxide nanomaterials have a promising application in nanomedicine. In recent years, the health impacts of nanomaterials and ultrafine particles have been paid attention. Due to a wide range of differences between the properties of nanomaterials among them and when compared to their bulk forms, there is a need to study both acute and chronic toxicities of these nanomaterials to assess their health impacts and toxicities in humans. In this review, application of nanomaterials in nano-medicine, toxicities of metal oxide nanomaterials and challenges before nano-drugs in pharmaceutical industry have been given an overview.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).